168 related articles for article (PubMed ID: 26613521)
21. Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.
Zhao S; Xu L; Liu W; Lv C; Zhang K; Gao H; Wang J; Ma R
Int J Clin Exp Pathol; 2015; 8(5):5744-8. PubMed ID: 26191291
[TBL] [Abstract][Full Text] [Related]
22. KLP-PI: a new prognostic index for luminal B HER-2-negative breast cancer.
Pan C; Bhandari A; Liu Y; Xia E; Lin L; Lv S; Wang O
Hum Cell; 2019 Apr; 32(2):172-184. PubMed ID: 30560509
[TBL] [Abstract][Full Text] [Related]
23. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
24. [The immunohistochemical growth fraction (Ki-67) of breast cancers: relations to tumor spread, tumor morphology and receptor testing].
Weikel W; Beck T; Rosenthal H; Herzog R
Geburtshilfe Frauenheilkd; 1989 Mar; 49(3):277-82. PubMed ID: 2566552
[TBL] [Abstract][Full Text] [Related]
25. High Ki-67 expression is a poor prognostic indicator of 5-year recurrence free survival in patients with invasive breast cancer.
Yang XQ; Wang FB; Chen C; Peng CW; Zhang JF; Li Y
Asian Pac J Cancer Prev; 2011; 12(11):3101-5. PubMed ID: 22393997
[TBL] [Abstract][Full Text] [Related]
26. Differential expression of prognostic factors and effect on survival in young (< or =40) breast cancer patients: a case-control study.
Hartley MC; McKinley BP; Rogers EA; Kalbaugh CA; Messich HS; Blackhurst DW; Lokey JS; Trocha SD
Am Surg; 2006 Dec; 72(12):1189-94; discussion 1194-5. PubMed ID: 17216817
[TBL] [Abstract][Full Text] [Related]
27. Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67.
Kumaki N; Umemura S; Tang X; Saito Y; Suzuki Y; Tokuda Y
Breast Cancer; 2011 Apr; 18(2):98-102. PubMed ID: 21290265
[TBL] [Abstract][Full Text] [Related]
28. Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score.
Gwin K; Pinto M; Tavassoli FA
Int J Surg Pathol; 2009 Aug; 17(4):303-10. PubMed ID: 19578051
[TBL] [Abstract][Full Text] [Related]
29. A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method.
Jang MH; Kim HJ; Chung YR; Lee Y; Park SY
PLoS One; 2017; 12(2):e0172031. PubMed ID: 28187177
[TBL] [Abstract][Full Text] [Related]
30. Importance of Ki-67 in human epidermal growth factor receptor 2 positive breast cancer.
Erdogan B; Turkmen E; Yalta TD; Usta U; Kodaz H; Hacibekiroglu İ; Tanriverdi O; Uzunoglu S; Cicin I
J BUON; 2015; 20(3):730-6. PubMed ID: 26214624
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of Ki67 for adjuvant chemotherapy in node-negative, hormone receptor-positive breast cancer.
Sutepvarnon A; Warnnissorn M; Srimuninnimit V
J Med Assoc Thai; 2013 Feb; 96 Suppl 2():S60-6. PubMed ID: 23590023
[TBL] [Abstract][Full Text] [Related]
32. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
[TBL] [Abstract][Full Text] [Related]
33. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer.
Billgren AM; Tani E; Liedberg A; Skoog L; Rutqvist LE
Breast Cancer Res Treat; 2002 Jan; 71(2):161-70. PubMed ID: 11881912
[TBL] [Abstract][Full Text] [Related]
35. Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis.
Loehberg CR; Almstedt K; Jud SM; Haeberle L; Fasching PA; Hack CC; Lux MP; Thiel FC; Schrauder MG; Brunner M; Bayer CM; Hein A; Heusinger K; Heimrich J; Bani MR; Renner SP; Hartmann A; Beckmann MW; Wachter DL
Breast Cancer Res Treat; 2013 Apr; 138(3):899-908. PubMed ID: 23479421
[TBL] [Abstract][Full Text] [Related]
36. Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells.
Hida AI; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Moriya T
Breast Cancer; 2015 Mar; 22(2):129-34. PubMed ID: 23543399
[TBL] [Abstract][Full Text] [Related]
37. Outcomes and recurrence patterns according to breast cancer subtypes in Korean women.
Lee Y; Kang E; Lee AS; Baek H; Kim EK; Park SY; Kim JH; Kim YJ; Kim SH; Kim IA; Eom KY; Kim SW
Breast Cancer Res Treat; 2015 May; 151(1):183-90. PubMed ID: 25893592
[TBL] [Abstract][Full Text] [Related]
38. The Long-term Prognostic Performance of Ki-67 in Primary Operable Breast Cancer and Evaluation of Its Optimal Cutoff Value.
Cho U; Kim HE; Oh WJ; Yeo MK; Song BJ; Lee A
Appl Immunohistochem Mol Morphol; 2016 Mar; 24(3):159-66. PubMed ID: 25789536
[TBL] [Abstract][Full Text] [Related]
39. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
[TBL] [Abstract][Full Text] [Related]
40. Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor.
Fehm T; Maul H; Gebauer S; Scharf A; Baier P; Sohn C; Jäger W; Gebauer G
Strahlenther Onkol; 2005 Sep; 181(9):580-6. PubMed ID: 16170485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
